MX2007007497A - Analogos de fosfolipido eter para la deteccion y tratamiento del cancer. - Google Patents

Analogos de fosfolipido eter para la deteccion y tratamiento del cancer.

Info

Publication number
MX2007007497A
MX2007007497A MX2007007497A MX2007007497A MX2007007497A MX 2007007497 A MX2007007497 A MX 2007007497A MX 2007007497 A MX2007007497 A MX 2007007497A MX 2007007497 A MX2007007497 A MX 2007007497A MX 2007007497 A MX2007007497 A MX 2007007497A
Authority
MX
Mexico
Prior art keywords
cancer
tumor
imaging
group
tumors
Prior art date
Application number
MX2007007497A
Other languages
English (en)
Spanish (es)
Inventor
Jamey Weichert
Marc Longino
Anatoly Pinchuk
Original Assignee
Cellectar Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectar Llc filed Critical Cellectar Llc
Publication of MX2007007497A publication Critical patent/MX2007007497A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2007007497A 2004-12-20 2005-12-20 Analogos de fosfolipido eter para la deteccion y tratamiento del cancer. MX2007007497A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59319004P 2004-12-20 2004-12-20
PCT/US2005/047657 WO2007013894A2 (en) 2004-12-20 2005-12-20 Phospholipid ether analogs for detecting and treating cancer

Publications (1)

Publication Number Publication Date
MX2007007497A true MX2007007497A (es) 2008-01-11

Family

ID=37564093

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007007497A MX2007007497A (es) 2004-12-20 2005-12-20 Analogos de fosfolipido eter para la deteccion y tratamiento del cancer.

Country Status (6)

Country Link
EP (1) EP1833514A2 (ko)
JP (1) JP2008545614A (ko)
KR (1) KR20080005178A (ko)
CA (1) CA2591907A1 (ko)
MX (1) MX2007007497A (ko)
WO (1) WO2007013894A2 (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8540968B2 (en) 2004-03-02 2013-09-24 Cellectar, Inc. Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
US7700075B2 (en) * 2004-07-08 2010-04-20 Cellectar, Llc Virtual colonoscopy with radiolabeled phospholipid ether analogs
DK1729824T3 (da) 2004-03-02 2009-11-02 Cellectar Inc Phospholipidanaloger til behandling af cancere
EP2429591B1 (en) * 2009-05-11 2015-08-26 Cellectar, Inc. Fluorescent phospholipid ether compounds, compositions, and methods of use
WO2010144788A2 (en) 2009-06-12 2010-12-16 Cellectar, Inc. Ether and alkyl phospholipid compounds for treating cancer and imaging and detection of cancer stem cells
WO2011031919A2 (en) * 2009-09-11 2011-03-17 Cellectar, Inc. Non-radioactive phospholipid compounds, compositions, and methods of use
SG11201703979QA (en) 2014-11-17 2017-06-29 Cellectar Biosciences Inc Phospholipid ether analogs as cancer-targeting drug vehicles
JP6666757B2 (ja) * 2016-03-10 2020-03-18 日本メジフィジックス株式会社 ポリオキシエチレン系非イオン界面活性剤の定量方法及び放射性医薬品製剤の製造方法
EP3469367B1 (en) 2016-06-14 2023-08-02 Cellectar Biosciences, Inc. Phospholipid ether analogs for the identification and isolation of circulating tumor cells
CA3031076C (en) * 2016-07-18 2023-10-03 Wisconsin Alumni Research Foundation Radiohalogenated agents for in situ immune modulated cancer vaccination
US11633506B2 (en) 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
CN109789207B (zh) * 2016-07-25 2022-11-18 威斯康星校友研究基金会 用于原位免疫调节的癌症疫苗接种的靶向放射治疗螯合物
EP3706808A1 (en) * 2017-11-10 2020-09-16 Wisconsin Alumni Research Foundation Using targeted radiotherapy (trt) to drive anti-tumor immune response to immunotherapies
EP3773754A4 (en) * 2018-04-10 2022-04-20 Cellectar Biosciences, Inc. FRACTIONAL DOSING OF A PHOSPHOLIPID ETHER ANALOGUE FOR THE TREATMENT OF CANCER

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5347030A (en) * 1987-10-23 1994-09-13 The Board Of Regents Of The University Of Michigan Radioiodinated phospholipid ether analogues and methods of using same
WO1998024480A1 (en) * 1996-12-04 1998-06-11 The Regents Of The University Of Michigan Radioiodinated phospholipid ether analogs and methods of using the same
US7700075B2 (en) * 2004-07-08 2010-04-20 Cellectar, Llc Virtual colonoscopy with radiolabeled phospholipid ether analogs
DK1729824T3 (da) * 2004-03-02 2009-11-02 Cellectar Inc Phospholipidanaloger til behandling af cancere

Also Published As

Publication number Publication date
KR20080005178A (ko) 2008-01-10
WO2007013894A9 (en) 2007-03-29
WO2007013894A3 (en) 2007-04-19
CA2591907A1 (en) 2007-02-01
EP1833514A2 (en) 2007-09-19
WO2007013894A2 (en) 2007-02-01
JP2008545614A (ja) 2008-12-18

Similar Documents

Publication Publication Date Title
US9579406B2 (en) Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof
MX2007007497A (es) Analogos de fosfolipido eter para la deteccion y tratamiento del cancer.
JP6453818B2 (ja) Ｄｉａｐｅｕｔｉｃ（登録商標）剤としてのリン脂質類似体、及びその方法
Chatalic et al. Towards personalized treatment of prostate cancer: PSMA I&T, a promising prostate-specific membrane antigen-targeted theranostic agent
US7700075B2 (en) Virtual colonoscopy with radiolabeled phospholipid ether analogs
Mease et al. PET imaging in prostate cancer: focus on prostate-specific membrane antigen
JP6953444B2 (ja) Ｐｅｔイメージング用免疫修飾因子
Harada et al. Preparation of asymmetric urea derivatives that target prostate-specific membrane antigen for SPECT imaging
Felber et al. Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?
Zhang et al. Synthesis, preclinical evaluation, and first-in-human PET study of quinoline-containing PSMA tracers with decreased renal excretion
Wu et al. Synthesis, preclinical evaluation, and first-in-human study of Al18F-PSMA-Q for prostate cancer imaging
JP7338128B2 (ja) 癌診断における放射性標識プロガストリン

Legal Events

Date Code Title Description
FA Abandonment or withdrawal